

APAC DAEWG

Progress in 2019

Atsushi Hasuoka

JPMA/Takeda

“DSANA” (Drug Seeds Alliance Network Asia) and “ANPDC” (APAC Natural Product Drug Discovery Consortium) made exciting progresses in 2019

- ✓ Information sharing about drug seeds between Taiwanese bioventures and Japanese pharmas
- ✓ Two Internships at Takeda
- ✓ Capacity building by Eisai


Web-based conference “WEB APAC DA Session” was held to confirm our progress and discuss your future direction

- ✓ Held 2 h web-based meeting on April 7
- ✓ Shared progress of “DSANA” and “ANPDC” by the leaders and hands-on researchers

Our goal and focused activity

Goal

“Promote cross-border open innovation in Asia to deliver innovative drugs to people in Asia”



Goal

“Promote cross-border open innovation in Asia to deliver innovative drugs to people in Asia”

Information Sharing

- ✓ Drug Seeds Alliance
Network Asia (DSANA)

Capacity Building of Researcher

- ✓ APAC Bio Japan DAEWG Session
- ✓ APAC Natural Product Drug
Discovery Consortium

*Cross-border open
innovation in Asia*

Human Network

- ✓ APAC DAEWG Research
Center Site Visit


Collaboration Platform

- ✓ APAC Natural Product Drug
Discovery Consortium

Schedule

Facilitator: Dr. Chi (DCB, Taiwan)

- 5 min Opening Remarks (Dr. Hasuoka)
- 10 min DSANA Overview (Dr. Terauchi)
- 15 min Progress and future plan (Mrs. April)
- information gathering from bioventures and participation in D-Bio,
future plan, lessons and learned, etc.
- 10 min ANPDC Overview (Dr. Nares)
- 30 min Progress in Thailand, lessons and learned and future plan (10 min X 3)
(1) Progress of ANPDC at ECDD (Dr. Suparerak)
(2) Progress of ANPDC at BIOTEC (Dr. Lily)
(3) Application of iPS disease model for screenings of natural products
(Dr. Nipan)
- 45 min Discussion
- Future direction based on our achievement and the current status
- 5 min Closing Remarks (Dr. Nares)



Key Concepts of DSANA

- Establish an Asian-wide information sharing platform to promote cross-boarder alliances in Asia
- Establish a database by collecting drug seeds information from academia and industry in Asia

Pilot project focusing on information sharing between Taiwan and Japan

- Collaborating with Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) and Drug Commercialization Center (DCC)
- 13 drug seeds information was incorporated into a database of OCCI
- 8 ventures were nominated based on the survey of Japanese pharmas
- BPIPO and DCB selected 4 ventures to join D-Bio conference in Osaka in Jan. 2020



4 invited Taiwanese ventures attended 15
F2F meetings at D-Bio conference

Key concept of ANPDC

Step 1: Capacity building of Asia researchers at Japanese pharma companies

- ✓ Japanese pharmas invite Asian researchers to support them to develop their capability for drug discovery

Step 2: Evaluation of natural products in Asian countries

- ✓ Asian researchers carry out screening of natural products using expertise they have acquired at Japanese pharmas after coming back to their home countries

Sustainable open innovation in Asia

The consortium is an Asian-wide collaboration platform to maximize the potential of natural products in drug discovery.

However, the consortium even more focuses on capacity building of Asian researchers who will lead drug discovery and open innovation in the near future



Internship at Takeda

1st internship: Mr. Phongthon Kanjanasirirat, Excellent Center for Drug Discovery (ECDD), Mahidol University, Thailand, 4 months from Feb. 1, 2019

2nd Internship: Miss Supawan Jamnongsong, Faculty of Medicine, Siriraj hospital, Mahidol University, from Feb. 1, 2020



Collaboration between BIOTEC and Eisai

BIOTEC and Eisai started collaboration in 2019!



BIOTEC-EISAI collaboration under the NPDD



Discussion at the 8th APAC Annual Meeting

APRIL, 2019 : TOKYO



Meeting at BIOTEC

AUGUST, 2019: PATHUMTHANI



Meeting at EISAI

OCTOBER, 2019 : TSUKUBA



THANK YOU